| Name | Title | Contact Details |
|---|
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Capital City Nurses is a Chevy Chase, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pam Gene is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Antech sets the standard for reference laboratory and imaging excellence. At the heart of our company is our love for pets, their health, and their…
EvidenceCare is the only decision support tool designed exclusively for clinicians that delivers evidence-based medicine individualized for each patient they treat. Our patent pending technology lowers costs and improves outcomes in a way that benefits patients, providers, payers, and clinics. We provide the evidence, so you can provide the care.